Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic
Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company…
Variational AI Secures $US3.5 Million in Seed Funding to Apply State-of-the-Art AI Platform to Generate Novel Small Molecule Therapeutics for Drug Development
Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecules, today announced that it has…
